Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos López, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 20, pp. 2304-2312
Open Access | Times Cited: 80

Showing 26-50 of 80 citing articles:

Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
Jorge Hernando, María Roca-Herrera, Alejandro García‐Álvarez, et al.
European Journal of Cancer (2023) Vol. 188, pp. 39-48
Open Access | Times Cited: 7
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial
Francesca Corti, Maria Pia Brizzi, Vito Amoroso, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
Kristen McClellan, Emerson Y. Chen, Adel Kardosh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4769-4769
Open Access | Times Cited: 12
Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications
Hannah Stowe McMurry, Jaydira Del Rivero, Emerson Y. Chen, et al.
Current Problems in Cancer (2024) Vol. 52, pp. 101131-101131
Closed Access | Times Cited: 2
Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms
Javier Pozas, María San Román, Teresa Alonso‐Gordoa, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 19, pp. 4949-4949
Open Access | Times Cited: 18
Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
Vera G. Megdanova-Chipeva, Ángela Lamarca, Alison Backen, et al.
Cancers (2020) Vol. 12, Iss. 7, pp. 1988-1988
Open Access | Times Cited: 18
Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors
Ugo Marchèse, Martin Gaillard, Anna Pellat, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 433-433
Open Access | Times Cited: 11
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)
Matthew H. Kulke, Fang‐Shu Ou, Donna Niedzwiecki, et al.
Endocrine Related Cancer (2022) Vol. 29, Iss. 6, pp. 335-344
Open Access | Times Cited: 11
Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta‐analysis
Hongxiao Wu, Xiaoyan Ding, Yongchao Zhang, et al.
Journal of Clinical Hypertension (2022) Vol. 24, Iss. 6, pp. 667-676
Open Access | Times Cited: 11
Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics
Virginia Corbett, Paul L. Hallenbeck, Piotr Rychahou, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 10
Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors
Xiuhua Lu, Shibin Yan, Kelly Koral, et al.
Expert Review of Anticancer Therapy (2021) Vol. 21, Iss. 9, pp. 917-926
Closed Access | Times Cited: 13
Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms
Osama Mosalem, Mohamad Bassam Sonbol, Þorvarður R. Hálfdánarson, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 5, pp. 101796-101796
Closed Access | Times Cited: 5
Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging
Junxiao Wang, Rui Liu, Yun Zhao, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 12
Case report: A case study on the treatment using icaritin soft capsules in combination with lenvatinib achieving impressive PR and stage reduction in unresectable locally progressive pancreatic cancer and a literature review
Xiaolong Liu, Feimin Yang, Dunmao Jia, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 4
Neoadjuvant therapy with peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours
Julie Hallet, Kjetil Søreide
British journal of surgery (2024) Vol. 111, Iss. 9
Open Access | Times Cited: 1
Non-Functioning Pancreatic Neuroendocrine Tumors
Nicola Fazio, Anna Koumarianou
Springer eBooks (2024), pp. 315-347
Closed Access | Times Cited: 1
Enhancer landscape of lung neuroendocrine tumors reveals regulatory and developmental signatures with potential theranostic implications
Ester Davis, Shani Avniel-Polak, Shahd Abu-Kamel, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 41
Open Access | Times Cited: 1
Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review
Rodrigo G. Taboada, Felícia P. Cavalher, Juliana F. Rego, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors
Brittany C. Fields, Reed I. Ayabe, Yongwoo David Seo, et al.
Current Oncology Reports (2024)
Closed Access | Times Cited: 1
Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations
Javier Pozas, Teresa Alonso‐Gordoa, Maria San Román, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2022) Vol. 1877, Iss. 5, pp. 188804-188804
Closed Access | Times Cited: 7
Advances in Management of Nonfunctional Pancreas Neuroendocrine Tumors
Alexandra W. Acher, Julie Hallet
Surgical Clinics of North America (2024) Vol. 104, Iss. 5, pp. 1095-1111
Closed Access | Times Cited: 1
Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors—Need for a Conductor
Alexander Siebenhüner, Melanie Langheinrich, Juliane Friemel, et al.
Cancers (2022) Vol. 14, Iss. 6, pp. 1478-1478
Open Access | Times Cited: 6
Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review
Bryan Khuong Le, Patrick W. McGarrah, Alan Paciorek, et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 3, pp. 403-414.e5
Open Access | Times Cited: 3
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
Taymeyah Al‐Toubah, Jonathan Strosberg, Julie Hallanger‐Johnson, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 3
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications
E Lauricella, Barbara Mandriani, Federica Cavallo, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 5

Scroll to top